Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

84.65EUR
20 May 2013
Price Change (% chg)

€0.53 (+0.63%)
Prev Close
€83.79
Open
€84.58
Day's High
€85.30
Day's Low
€83.89
Volume
1,087,157
Avg. Vol
2,327,644
52-wk High
€85.67
52-wk Low
€47.62

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 0.78
Market Cap (Mil.): €69,562.85
Shares Outstanding (Mil.): 826.95
Dividend: 1.90
Yield (%): 2.26

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 27.22 35.67 35.85
EPS (TTM): 3.09 -- --
ROI: 6.59 19.40 18.76
ROE: 12.89 20.11 19.57
Search Stocks

German stocks - Factors to watch on May 21

FRANKFURT, May 21 - The DAX top-30 index looked set to open 0.2 percent lower on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0620 GMT.

2:32am EDT

Bayer says lung drug shows promise in prolonged trial

FRANKFURT - Bayer said extended use of its experimental riociguat pill to treat a life-threatening form of high blood pressure in the lungs was shown to be safe and effective in a prolonged trial.

20 May 2013

Bayer to acquire herbal medicine maker Steigerwald

FRANKFURT, May 16 - Germany's largest drugmaker Bayer said it agreed to buy privately held Steigerwald Arzneimittelwerk GmbH, a maker of herbal treatments.

16 May 2013

Bayer, Algeta win FDA approval for prostate cancer drug

FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

15 May 2013

Bayer's plastics chief sees room to raise prices

LEVERKUSEN, Germany - Bayer suggested there was room to lift prices at its high-tech plastics and chemicals business this year to counter soaring raw material costs that squeezed first quarter margins.

10 May 2013

Court tells Bayer to compensate Schering shareholders

FRANKFURT, May 6 - A court ruled that Bayer did not pay some former Schering shareholders enough to acquire its German rival in 2007 and must now pay them more than 300 million euros ($392 million) in compensation, lawyers for the shareholders said.

06 May 2013

Bayer stops drug trial with haemophilia drug BAY 86-6150

FRANKFURT, May 3 - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

03 May 2013

Bayer to buy birth-control devices maker for $1.1 billion

FRANKFURT - Germany's Bayer AG has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider,

29 Apr 2013

UPDATE 1-Bayer to buy birth-control devices maker for $1.1 bln

* Purchase of Concetpus is latest in string of bolt-on deals

29 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Finlabo SIM Spa
$58.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$127.00
Provider: Wright Reports
$472.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks